From Fragmented to Unified: Building an Omnichannel Strategy for Complex B2B Buying Committees

Larry Hines • April 21, 2026

There's a conversation that happens in a lot of life sciences marketing teams, usually triggered by a lost deal or a pipeline review that doesn't add up. Someone asks: "How did they find us?" And the answer is almost always more complicated than anyone expected. They read a blog post six months ago. They saw you at a conference. Someone on their team got an email. Their scientist looked you up after a webinar. Their procurement lead ran a Google search. Nobody talked to sales until month four.

This is the reality of modern B2B buying in life sciences — and it's the reason omnichannel strategy matters as much as it does. The challenge in 2026 isn't deciding where to show up. It's making every touchpoint feel like part of the same coherent conversation, whether a buyer encountered you on LinkedIn last Tuesday or at a tradeshow six months ago.

The Buying Committee Problem

Before getting into tactics, it helps to name the specific challenge that makes omnichannel strategy genuinely hard in life sciences. You're rarely selling to one person. Capital equipment purchases might involve a principal investigator or lab director who evaluates technical and clinical fit, a procurement team focused on price and vendor compliance, an IT or informatics stakeholder who cares about integration and data security, and a C-suite or finance lead who signs off on budget. Each of these people has different questions, different information sources, and different definitions of a good vendor.

Generally, they don't coordinate their research with each other. They're consuming content independently, at different points in the buying cycle, through different channels. And they're forming opinions about your company long before anyone on your team knows they exist. An omnichannel strategy for this environment isn't about broadcasting the same message everywhere. It's about understanding who is likely to show up on which channel, what they need to see when they get there, and how to make those separate encounters feel like a continuous, coherent brand experience.

What "Omnichannel" Actually Means (And What It Doesn't)

The word gets misused enough that it's worth being direct about the distinction. Multichannel marketing means being present on multiple channels. You have a website, a LinkedIn page, an email program, and you exhibit at conferences. Each channel operates independently. The email team (I’m using “team” loosely; often this is one person) doesn't know what happened at the tradeshow. The website doesn't reflect what sales is saying in conversations. The LinkedIn content has nothing to do with the nurture sequence someone is getting in their inbox.

Omnichannel marketing means those channels are coordinated. The story a buyer hears on LinkedIn connects to the content they find on your website, which connects to the follow-up they receive after downloading a white paper, which connects to the conversation a sales rep has with them three months later. Every touchpoint knows, in some sense, what the others have been saying. The gap between these two states is where most life sciences companies currently live. They're multichannel by presence and siloed by execution. Fixing that gap is the actual work of your omnichannel strategy.

The Channels That Matter Most in Life Sciences B2B

Not every channel deserves equal investment, and life sciences buying behavior is specific enough to make some clear prioritization possible.

LinkedIn is the primary digital channel for professional discovery and brand building in this space. Decision-makers, scientists, and procurement leads all have a LinkedIn presence, and it's where thought leadership content gets the most traction. For companies targeting a defined set of accounts, LinkedIn's targeting capabilities — by job title, company, industry, seniority — are genuinely valuable, and they're not dependent on third-party cookies. Organic content from company leadership builds familiarity over time; paid campaigns can accelerate awareness with specific personas at specific accounts. Side note: LinkedIn is primarily a brand-building channel in this context, not a lead generation engine — the platform's value lies in creating familiarity and credibility with the right audiences over time, not in driving direct conversions from a single post or campaign.

Email remains one of the highest-ROI channels in B2B when it's done well. This means segmented, relevant, and paced for a long buying cycle. A scientist interested in mass spectrometry, and a procurement lead evaluating vendor compliance should not be receiving the same email sequence nor messaging. The ability to tailor content to the role and buying stage is what separates email programs that generate pipeline from email programs that generate unsubscribes.

Content, SEO, and AEO function as the always-on layer of your omnichannel strategy. When a buyer is in independent research mode (which, in life sciences, is most of the time), they're searching for answers through both traditional search engines and increasingly through AI-powered answer engines like ChatGPT, Perplexity, and Claude. Being present at those moments — whether as a ranked result in Google or as a cited source in an AI-generated answer — requires genuinely useful, technically credible content that is structured for both human readers and AI retrieval. Blog posts, white papers, application notes, and FAQs all serve this function, and when built with both SEO and AEO in mind, they extend your brand's reach across every channel where independent buyer research is happening.

Tradeshows and events remain disproportionately important in life sciences relative to other industries. The concentration of relevant buyers at events like the American Academy of Clinical Research (AACR), Society of Toxicology (SoT), or the Radiological Society of North America (RSNA) creates relationship-building opportunities that digital channels can't fully replicate. But events work best as part of an omnichannel sequence, not as standalone tactics. More on this in a future post specifically on tradeshow strategy.

Direct outreach and sales engagement is the channel where the buying committee question becomes most acute. Sales reps need to know what each contact has engaged with, what channel they came from, and where they are in their evaluation. Without that context, outreach feels generic and the relationship starts from zero even when the prospect has already consumed significant content.

Building Coordination Across Channels

The tactical question is how to actually connect these channels so they function as a system rather than a collection of independent programs.

Start with your CRM and marketing automation platform as the connective tissue. Every meaningful digital interaction — content downloads, email opens and clicks, webinar registrations, website page visits, form fills — should be captured in a system that gives both marketing and sales visibility into what a contact or account has engaged with. HubSpot, Marketo, and Salesforce Marketing Cloud are the most common platforms in this space. If your CRM and marketing automation aren't talking to each other, channel coordination is almost impossible to achieve.

Build content for the full buying committee, not just one persona. Map your content assets to the specific questions each stakeholder is asking at each stage of the buying process. Technical application notes and scientific webinars for the research and evaluation stakeholders. ROI frameworks, vendor evaluation guides, and compliance documentation for procurement and finance. Executive-level thought leadership for C-suite contacts. When a buying committee member arrives at your website or LinkedIn page, they should quickly find content that speaks to their specific context.

Use account-level engagement as your coordination signal. In a buying committee sale, individual lead scores can be misleading. What matters is whether the account as a whole is showing increased engagement across multiple contacts and channels. This is the logic behind account-based marketing: rather than tracking individual leads in isolation, you track account-level activity and use that signal to coordinate timing and messaging across channels. When multiple stakeholders at the same account are engaging simultaneously, that's a signal worth acting on.

Make your brand voice consistent across every channel. This sounds obvious and is surprisingly hard to execute. The tone and perspective in your LinkedIn posts should match the voice in your email nurture sequences, which should match what a sales rep says in an introductory call. When these feel misaligned, buyers notice, and it creates a subtle but real trust erosion. Messaging architecture (which we'll cover in a dedicated post on positioning) provides the foundation for this consistency.

The Measurement Challenge

Omnichannel strategy introduces a measurement complexity that simpler, single-channel programs don't face: when a deal closes after a buyer has touched six different channels over eight months, which channel gets credit? The honest answer is that no attribution model handles this perfectly. Last-click attribution, which is still the default in many organizations, dramatically overstates the role of the final touchpoint and undercounts everything that built awareness and consideration earlier in the cycle. Realistically, there’s no one marketing tactic or channel that is going to convert a complex life science sale on its own. It’s always the sales representative and science/technical support that are 100% responsible for making these complex sales. Marketing is a critical lever to build brand awareness and equity; soften the market so it’s prepared to hear how the product or service will solve their problems; and deliver market and customer insights that fuel the next innovation.

At the same time, we must be able to evaluate our multi-channel campaigns and understand whether we are reaching the appropriate target audience with the correct messaging and influencing the final decision. Multi-touch attribution is better in theory but requires clean data across all channels and a level of technical integration that some marketing teams haven't achieved. The practical approach is to use attribution models directionally rather than definitively, supplement them with direct conversation (asking buyers in sales calls and onboarding surveys how they found you and what influenced their decision), and focus reporting on pipeline contribution and revenue influence rather than trying to achieve perfect attribution precision.

What you're ultimately trying to measure is whether the coordinated system is working: are target accounts progressing through the buying cycle? Are multiple stakeholders within key accounts engaging? Is the handoff from marketing to sales happening with enough context to make sales conversations more productive?

The Real Goal

Omnichannel strategy is sometimes presented as a technology problem, a question of which platforms to integrate and which tools to deploy. Technology enables it, but the underlying goal is simpler and more human than any platform. The goal is to make every buyer feel like your company already understands them when they finally raise their hand. That the sales rep who calls knows what they've read. That the proposal reflects the specific concerns they've expressed. That the brand they've been encountering across channels for the past several months feels like a coherent, credible, trustworthy partner for a high-stakes decision.

In life sciences, where the buying cycle is long, the buying committee is complex, and trust is the deciding factor in most competitive situations, that feeling of coherence is worth more than any individual channel can deliver on its own. That's what an omnichannel strategy actually builds.

I work with life sciences companies on digital marketing strategy, from SEO and content to demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more. If this resonated, or if you have a different perspective, I'd genuinely like to hear from you.

Contact Us

< Older Post

A person uses a stylus on a digital tablet, interacting with a glowing, blue digital interface overlaying a laptop.

Demand Generation in a Cookieless World: Intent Signals That Work

By Larry Hines • March 27, 2026

Demand Generation in a Cookieless World: Intent Signals That Actually Work If you've been in B2B marketing for more than a few years, you've lived through at least one version of this conversation: the tools we've relied on are changing, the old playbook is breaking down, and we need to figure out what comes next. The death of the third-party cookie is that conversation's current chapter. And while it's been a slow-moving story (Google has delayed the full removal of third-party cookies in Chrome more times than most of us can count), the direction of travel is clear. The targeting infrastructure that B2B demand generation has leaned on heavily for the past decade is eroding, and the marketers who adapt early will have a real advantage over those who wait for the change to force their hand. The good news: the alternatives aren't just adequate. In many cases, they're better. What We're Actually Losing To understand what to replace, it helps to be specific about what third-party cookies actually did for demand generation. They enabled cross-site tracking, following a user from your website to other websites and building a behavioral profile over time. That profile powered retargeting campaigns, lookalike audience modeling, and the kind of frequency-capped, multi-touch display advertising that kept your brand in front of prospects who had visited your site but hadn't converted. For life sciences companies with long sales cycles and diffuse buying committees, that persistence mattered. A scientist who visited your product page in January and then saw a relevant ad in March was being nudged along a journey that third-party cookies made possible. Without them, that specific mechanism breaks. But what it leaves behind is a reason to build something more durable. First-Party Data: The Foundation You Should Have Been Building Anyway The most important shift in cookieless demand generation is the move from renting an audience to owning one. First-party data, meaning information your prospects and customers give you directly through their interactions with your owned channels, is both more valuable and more durable than anything you could buy or borrow through third-party tracking. In practice, building first-party data for a life sciences company means creating genuine reasons for your audience to identify themselves to you. Gated content that's worth gating: original research, technical white papers, protocol guides, benchmark reports. Not the "download our brochure" variety that nobody trades their email address for anymore. Webinars and virtual events that attract real practitioners. Newsletter subscriptions that deliver actual value. Demo requests and product trials that signal high intent. The quality of what you're offering in exchange for contact information determines the quality of the audience you build. If you're generating a list of email addresses attached to people who downloaded a generic industry overview, you have a weak asset. If you're generating a list of scientists and lab managers who consumed a detailed technical guide on automating lab workflows, you have something genuinely useful. The investment required to build that kind of first-party asset is higher. The returns are proportionally better. Intent Signals: Reading the Room Without Cookies Beyond first-party data, the cookieless world has accelerated the maturation of intent data as a demand generation tool, and this is where things get interesting. Behavioral signals on your own properties are the clearest intent indicators you have. Someone who visits your product page, reads three blog posts, downloads a technical guide, and then visits your pricing page is telling you something important without saying a word. Marketing automation platforms like HubSpot, Marketo, and Pardot have always been able to track this within your environment, and this capability is unaffected by the discontinuation of cookies. If you're not using progressive lead scoring based on on-site behavior, that's a high-priority gap to close. Third-party intent data platforms like Bombora, TechTarget Priority Engine, and G2 Buyer Intent aggregate signals from across the web: content consumption patterns, review site activity, category research. These platforms use their own first-party data, collected with consent on their own properties, to build intent signals that are not dependent on third-party cookies. For life sciences companies targeting a defined set of accounts, layering intent data onto your ABM programs can dramatically improve prioritization, letting you focus sales and marketing energy on the accounts that are actually in a buying motion right now. Social and community signals are harder to track but increasingly important. A significant portion of B2B buying research happens in places that are essentially invisible to traditional analytics: private Slack communities, LinkedIn DMs, industry forums, and conference conversations. You can't measure this directly, but you can influence it. Active participation in relevant communities, a strong LinkedIn presence, and a reputation for producing content that practitioners share with each other all build influence in these channels. When a scientist asks their peer network "who do you use for lab automation," you want your name to come up. Search intent data, available through tools like SEMrush, Ahrefs, and Google Search Console, tells you what your target audience is actively searching for, which is a proxy for what they're thinking about. Mapping keyword intent to your content and paid search strategy ensures you're present at the moments when intent is highest and most legible. ABM as the Organizing Framework In a world where broad-based retargeting is harder, Account-Based Marketing becomes a more attractive organizing framework for demand generation. Rather than casting a wide net and hoping the algorithm finds the right people, ABM starts with a defined list of target accounts and orchestrates marketing activity specifically around those accounts. For life sciences companies, where the total addressable market is often well-defined, deal sizes are meaningful, and sales cycles are long, ABM is a natural fit regardless of the cookie situation. But the cookieless transition makes it more compelling still, because the precision of ABM reduces the dependence on the broad behavioral tracking that third-party cookies enabled. A well-executed ABM program in this environment combines intent data to prioritize accounts, first-party content assets to attract and engage them, LinkedIn targeting to reach specific personas within those accounts, and tight sales and marketing alignment to ensure that when an account raises its hand, someone is ready to respond quickly. It's not a simple motion to run. But for complex B2B sales in life sciences, it's the right one. What This Means for Your Measurement Approach One underappreciated consequence of the cookieless shift is that it breaks some of the attribution models demand generation teams have relied on. Multi-touch attribution that tracked a prospect's journey across multiple sites and sessions becomes harder to reconstruct without third-party cookies. The response isn't to abandon measurement. It's to diversify it. Alongside whatever digital attribution your tools can still support, invest in direct conversation with your customers and prospects about how they found you and what influenced their decision. Ask in sales calls. Include it in onboarding surveys. Run periodic voice-of-customer research. The qualitative signal you get from simply asking people is often more accurate than the algorithms that were never as reliable as they looked. Pipeline contribution, account engagement scores, and revenue influence are also more durable metrics than last-click or multi-touch attribution models that depend on complete tracking data. Orient your reporting around what you can measure reliably, and be honest about the limits of what you can't. The Underlying Point The cookieless transition is genuinely disruptive to some of the tactics demand generation has relied on. But the fundamentals it pushes you toward, including owned audience, genuine content value, intent-based prioritization, and account focus, are better marketing practices than what they're replacing. The brands that treat this as a trigger to build something more durable will emerge stronger. The ones waiting for a technical workaround that recreates the old model are likely to be disappointed. Build the asset. Earn the attention. Read the intent. That's the playbook. I work with life sciences companies on digital marketing strategy, from SEO and content to demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more. If this resonated, or if you have a different perspective, I'd genuinely like to hear from you.

The Answer Engine Era: Getting Your Brand Cited by AI — and Why It Matters

By Larry Hines • March 25, 2026

The Answer Engine Era: Getting Your Brand Cited by AI — and Why It Matters Now Something fundamental has shifted in how people find information. For most of the internet's history, the search box was a gateway — you typed a question, Google returned a list of doors, and you chose which one to open. That model isn't disappearing, but it's increasingly sharing the stage with something different. Answer engines don't give you options. They give you answers. And if your brand isn't part of those answers, you're invisible in a way that doesn't even show up in your Google Search Console data. This is the world of Answer Engine Optimization (AEO) and its close cousin, Generative Engine Optimization (GEO.) If those terms are new to you, you're not alone. The terminology is still settling across the industry. But the underlying shift is real, it's accelerating, and for life sciences companies, understanding it now is a genuine competitive advantage. What We're Actually Talking About When someone opens ChatGPT and asks "what are the leading lab automation platforms for drug discovery," they're not getting ten blue links. They're getting a synthesized answer, drawn from the model's training data, sometimes supplemented by real-time web retrieval, which names specific companies, describes their capabilities, and frames the competitive landscape. The same is true of Perplexity, Gemini, Claude, and Microsoft's Copilot, a rapidly expanding set of platforms where buyers are increasingly starting their research. If your company isn't mentioned, you don't exist in that answer. Perplexity operates with heavy real-time web retrieval; it's actively pulling from current sources and synthesizing them into a cited response. Google's Gemini is doing the same within the Google ecosystem. Microsoft's Copilot is weaving this into enterprise workflows. The common thread: a user asks a question, AI synthesizes an answer, and the brands that get named are the ones that have built the right kind of digital presence. AEO and GEO are about understanding what that "right kind of presence" looks like, and building it deliberately. Why Life Sciences Companies Are Both Vulnerable and Well-Positioned Here's the uncomfortable truth: many life sciences companies are poorly set up for the answer engine era. Websites that are heavy on product specs and light on educational content, minimal third-party validation, sparse publishing histories, and technical jargon that even an AI struggles to contextualize. These are characteristics that make a company easy to overlook when a model is synthesizing an answer about a category. But there's an opportunity. The barriers to being cited are largely content and authority barriers, not technical ones. And life sciences companies that have real expertise, genuine innovation, and credible science behind their products have exactly what it takes to build the kind of presence that gets noticed. The playing field is more level than it looks if you know what you're building toward. What Makes a Brand Citable Think about how a well-read expert synthesizes an answer when someone asks them a question. They draw on sources they trust; sources that are authoritative, consistent, clearly written, and specific. AI models do something similar, and the factors that make a source trustworthy to a human map well to what makes content citable by AI. Clarity and structure matter enormously. Content that answers questions directly with clear headings, logical organization, and specific rather than vague language is far more likely to be pulled into a synthesized answer than content that buries its point in marketing copy. If someone asks AI "how does a mass spectrometer work," and your website has a well-structured, clearly written page that explains exactly that, you're a candidate to be cited. If your page leads with "transforming the future of drug discovery" and takes three paragraphs to get to anything substantive, you're not. Specificity beats generality. AI models are reasonably good at synthesizing general answers. They're much more likely to cite a source that offers something specific like a number, a mechanism, a named methodology, or a concrete outcome that adds to the answer rather than restating it. Original data, proprietary frameworks, and specific use cases are your most citable assets. Consistent topical authority signals matter. Being cited isn't just about having one good page. Models learn to associate sources with topics over time, through the accumulation of relevant, high-quality content. A company that has published consistently on a topic builds a form of topical authority that makes it a go-to reference when that topic comes up in a query. Third-party validation amplifies everything. Being mentioned, quoted, or cited by other credible sources such as industry publications, conference proceedings, peer-reviewed content, and reputable blogs tells AI models that your brand is recognized by the broader community of knowledge on a topic. This is essentially the AEO equivalent of link building in traditional SEO, and it carries real weight. Practical Steps to Start Building for AEO You don't need to overhaul your entire content strategy overnight. A few focused moves will start building your AEO presence meaningfully. Audit your existing content for answerability. Go through your key pages and ask honestly: if someone asked AI the question this page is trying to answer, would this content give the model something useful to work with? Look for pages that are vague, jargon-heavy, or structured around marketing messaging rather than genuine education. Those are your highest-priority rewrites. Develop an FAQ architecture. One of the most reliable AEO tactics is building out robust FAQ content; content that's genuine, substantive, and answers the questions your buyers are actually asking. " How would DIA acquisition with AI-assisted spectral matching change peptide identification rates and quantitative reproducibility in a high-throughput Orbitrap proteomics workflow?" is the kind of question a serious buyer might put to an AI. If you have a thoughtful, specific answer on your site, you're a step ahead. Pursue earned mentions deliberately. Identify the publications, platforms, and voices in your space that AI models are likely to draw from, and develop a strategy for getting mentioned there. Guest articles, contributed content, interview placements, and active participation in industry conversations all build the third-party citation trail that supports AEO authority. Implement structured data. Schema markup (the technical layer that helps search engines and AI systems understand what your content is about) is more important than ever. Organization schema, FAQ schema, and article schema in particular help models correctly categorize and retrieve your content. Create content that AI queries are likely to surface. Think about the questions your buyers are putting to AI tools right now. Map those questions to content on your site or create that content if it doesn't exist. The Bigger Picture AEO and GEO are not replacements for SEO. They're an expansion of the playing field. The fundamentals (clear content, genuine expertise, credible authority) are consistent across both. What changes is the format of the competition and the nature of the reward. In traditional SEO, winning means a high-ranking blue link. In the answer engine era, winning means being part of the answer itself. For life sciences companies with real science, real expertise, and real results to talk about, that's an opportunity that needs to be taken seriously. The brands that start building now will have a meaningful head start. The category is still early enough that doing the basics well puts you ahead of the majority of your competitors. That window won't stay open forever. I work with life sciences companies on digital marketing strategy -- from SEO/AEO/GEO , content marketing, demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more. If this resonated — or you have a different take — I'd genuinely like to hear from you.

Beyond Keywords: How Google's AI Overviews Are Rewriting the Rules of Organic Search

By Larry Hines • March 24, 2026

For the better part of two decades, the rules of SEO were relatively stable. Yes, Google's algorithm evolved constantly, from Panda to Penguin to BERT, but the fundamental game remained the same. Research keywords, create content, build authority, earn rankings, get clicks. Rinse and repeat. That game hasn't ended. But it's changed more in the last eighteen months than it did in the previous ten years combined. And if you're still playing by the old rules, you're likely wondering why your organic traffic numbers look different than they used to. The culprit, or the catalyst, depending on how you look at it is AI Overviews. What AI Overviews Actually Do (And Why It Matters) If you've searched Google recently, you've seen them: that block of AI-generated text that appears above the organic results, synthesizing an answer before you've clicked a single link. Google calls them AI Overviews. The SEO community has a lot of other names for them, some not suitable for professional publishing. The core tension is straightforward. Google built its business on sending people to websites. AI Overviews, at their most extreme, answer the question so completely that there's no reason to click through at all. This phenomenon — getting an answer without visiting a source — is what researchers call "zero-click search," and it's accelerating. Early data suggests that for informational queries, AI Overviews can reduce organic click-through rates significantly. Some studies have put that figure at 20–30% for affected query types, though the numbers vary by industry and search intent. For life sciences companies that have invested heavily in educational content — explainer pages, FAQs, how-it-works guides — this is not a theoretical concern. It's a traffic reality that's already showing up in Google Search Console. The Queries That Are Most Affected Not every search is equally impacted, and understanding where AI Overviews appear — and where they don't — is the first step to adapting your strategy. AI Overviews tend to dominate informational queries: "how does lab automation work," "what is a LIMS system," "difference between flow cytometry and mass cytometry." These are the educational, top-of-funnel questions that life sciences companies have been optimizing for years. They appear far less frequently on commercial and transactional queries; searches that signal buying intent. "Lab automation vendors," "best LIMS for biotech," "request a demo", etc. are still, largely, territory where traditional organic listings and paid results hold the real estate. The practical implication: your middle-of-funnel and bottom-of-funnel content (comparison pages, use case content, solution pages) may actually be more valuable now than your purely educational content. The informational stuff will increasingly get absorbed into AI Overviews. The "help me decide" and "I'm ready to explore options" content is where organic clicks are more likely to survive. What "Ranking" Even Means Now Here's where things get philosophically interesting, and where I think a lot of marketers are still catching up. Ranking used to mean appearing in positions one through ten on a results page. The goal was a blue link, a meta description, and a click. That mental model is increasingly incomplete. There are now effectively two valuable positions in a Google search result: Being cited within an AI Overview. Google pulls sources for its AI-generated answers, and those sources are often linked. Appearing as a cited source in an AI Overview can actually drive meaningful traffic — arguably more qualified traffic, since the user has already had their question partially answered and is clicking through for more depth or credibility. Ranking below the AI Overview for queries where users still scroll. For complex, high-stakes decisions, which describe most B2B life sciences purchases, users often distrust a synthesized answer and want to read the source material. A strong position three or four below an AI Overview can still convert well if your snippet is compelling. What's less valuable than it used to be: ranking for purely informational queries where a thorough AI Overview already satisfies the search intent completely. Traffic from those positions is declining, and in many cases no amount of optimization will recover it. So What Should You Actually Do? Here's what's working: Shift your content investment toward specificity and depth. AI Overviews are reasonably good at synthesizing general answers. They're much weaker at capturing nuanced, experience-based, or highly specific content. A blog post titled "How lab automation affects your GMP compliance workflows" will hold its value far longer than one titled "What is lab automation." The more your content reflects genuine expertise and specific use cases, the less substitutable it is. Build for citation, not just for ranking. Google's AI Overviews cite sources that demonstrate clear authority on a topic. This means structured, well-organized content with strong E-E-A-T signals -- Experience, Expertise, Authoritativeness, Trust. It means having credible authors, proper schema markup, clean site architecture, and original data or perspective that makes you citable rather than paraphraseable. We'll go deeper on E-E-A-T in a future post specifically on this topic. Rethink your keyword strategy around intent tiers. Audit your existing keyword targets and honestly categorize them: informational (at risk), commercial (more protected), transactional (largely protected). Rebalance your content calendar accordingly. If 80% of your planned content is informational, you have concentration risk. Double down on conversion optimization for the traffic you do get. If overall organic volume is declining, the math only works if your conversion rate improves. This means better CTAs, stronger landing page experiences, more compelling lead magnets, and tighter alignment between what your content promises and what happens when someone clicks through. Fewer visitors who convert at a higher rate can outperform more visitors who bounce. Use Google Search Console to find your specific exposure. Every site is different. Pull your top informational queries and check whether AI Overviews are appearing for them. Look at your click-through rate trends over the past twelve months. The data will tell you exactly where the impact is landing in your specific situation — which is always more useful than industry averages. The Bigger Strategic Point There's a temptation to treat AI Overviews as a problem to be solved, a new obstacle to route around. What AI Overviews actually represent is Google making a judgment about what searchers want: faster, more direct answers to general questions. That's not going away. The companies that will win organic search over the next five years are the ones that stop competing on who can produce the most comprehensive answer to a generic question, and start building genuine authority through original research, deep expertise, specific use cases, and strong points of view In life sciences, that advantage is more available than in almost any other sector. The science is complex, the buying decisions are high-stakes, and the questions that serious buyers are asking can't be fully answered by a paragraph of AI-generated text. That's your opening. The marketers who figure this out early will look very smart in two or three years. The ones still optimizing keyword density are going to have a rough time. I work with life sciences companies on digital marketing strategy, from SEO and content to demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more . If this resonated — or if you disagree with any of it — I'd genuinely like to hear from you.